Guangbin Peng

722 total citations
24 papers, 549 citations indexed

About

Guangbin Peng is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Guangbin Peng has authored 24 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 5 papers in Surgery. Recurrent topics in Guangbin Peng's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Guangbin Peng is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Guangbin Peng collaborates with scholars based in United States, Italy and China. Guangbin Peng's co-authors include Coleman K. Obasaju, Matthew Monberg, Giorgio V. Scagliotti, Mark A. Socinski, Lina Asmar, Jane Bromund, Joseph Treat, Lars Viktrup, Richard C. Bump and Corey J. Langer and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and CHEST Journal.

In The Last Decade

Guangbin Peng

24 papers receiving 540 citations

Peers

Countries citing papers authored by Guangbin Peng

Since Specialization

Citations

This map shows the geographic impact of Guangbin Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangbin Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangbin Peng more than expected).

Fields of papers citing papers by Guangbin Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangbin Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangbin Peng. The network helps show where Guangbin Peng may publish in the future.

Co-authorship network of co-authors of Guangbin Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Guangbin Peng. A scholar is included among the top collaborators of Guangbin Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangbin Peng. Guangbin Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acupuncture for Fibromyalgia: A Review Based on Multidimensional Evidence 2023 ·The American Journal of Chinese Medicine ·Dong Woo Han, Yuan Lu, Rong Huang, Zihui Yang, Guangbin Peng, Yu Qiao, Xiyin Zhang, Huangan Wu, Huirong Liu	6
2	Rationale and Design of the Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy (RESTORE) Study (P5.131) 2016 ·Neurology ·Randall Owen, Guangbin Peng, (unknown), (unknown), Gerald J. Rowse	1
3	Deconstructing tolerance with clobazam 2016 ·Neurology ·Barry E. Gidal, Robert Wechsler, Raman Sankar, Georgia Montouris, H. Steve White, James C. Cloyd, (unknown), Guangbin Peng, (unknown), (unknown), Jouko Isojärvi	11
4	Clobazam for Dravet Syndrome: Designing a Clinical Study Using Pharmacokinetic/Pharmacodynamic Modeling (P1.260) 2015 ·Neurology ·Deborah Lee, (unknown), (unknown), (unknown), (unknown), Guangbin Peng, Dwain Tolbert	2
5	Intravenous carbamazepine as short‐term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open‐label trials 2015 ·Epilepsia ·Deborah Lee, (unknown), Jonathan J. Halford, Victor Biton, James C. Cloyd, Pavel Klein, Ihor Bekersky, Guangbin Peng, (unknown), Dwain Tolbert	7
6	An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: Inferior outcomes for African American males in the LORHAN database 2014 ·Oral Oncology ·D. Neil Hayes, Guangbin Peng, Eduardo J. Pennella, Anwar Hossain, Gebra Cuyún Carter, Catherine E. Muehlenbein, Coleman K. Obasaju	14
7	Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer 2013 ·Journal of Thoracic Oncology ·Hak Choy, Lee S. Schwartzberg, Shaker R. Dakhil, Edward B. Garon, David E. Gerber, J. K. Choksi, Ramaswamy Govindan, Guangbin Peng, Andrew Koustenis, Joseph Treat, Coleman K. Obasaju	27
8	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer 2012 ·Lung Cancer ·Myung‐Ju Ahn, James Chih‐Hsin Yang, (unknown), (unknown), Qingyu Xiu, Yuh‐Min Chen, Julie M. Blair, Guangbin Peng, Carlos Linn, Mauro Orlando	22
9	Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Sandrine Faivre, Anthony J. Olszanski, Karin Weigang-Koehler, Hanno Riess, Guangbin Peng, Sophie Callies, Karim A. Benhadji, Éric Raymond	4
10	Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non–Small-Cell Lung Cancer 2011 ·Clinical Lung Cancer ·Waldo Ortuzar, Nasser H. Hanna, Eduardo J. Pennella, Guangbin Peng, Corey J. Langer, Matthew Monberg, Giorgio V. Scagliotti	24
11	Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials 2011 ·Lung Cancer ·Joseph Treat, Giorgio V. Scagliotti, Guangbin Peng, Matthew Monberg, Coleman K. Obasaju, Mark A. Socinski	37
12	Synthesis and characterization of Parylene C/nanosilica composite film 2011 ·Applied Surface Science ·(unknown), Jingquan Liu, Qing He, Guangbin Peng, Chunsheng Yang	10
13	Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial 2010 ·Journal of Thoracic Oncology ·J.H. Heinzerling, Hak Choy, Randall Hughes, Ramaswamy Govindan, Jeffrey D. Bradley, Lee S. Schwartzberg, Guangbin Peng, Joseph Treat, (unknown), Coleman K. Obasaju	7
14	Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology 2010 ·Clinical Lung Cancer ·Ralph Zinner, Scott Saxman, Guangbin Peng, Matthew Monberg, Waldo Ortuzar	13
15	Comparison of Patient Outcomes According to Histology Among Pemetrexed-Treated Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer in Two Phase II Trials 2010 ·Clinical Lung Cancer ·Ralph Zinner, Silvia Novello, Guangbin Peng, Roy S. Herbst, Coleman K. Obasaju, Giorgio V. Scagliotti	17
16	Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer 2009 ·CHEST Journal ·M. Patricia Rivera, Frank C. Detterbeck, Mark A. Socinski, Dominic T. Moore, Martin J. Edelman, Thierry Jahan, Rafat Ansari, James D. Luketich, Guangbin Peng, Matthew Monberg, Coleman K. Obasaju, Richard J. Gralla	27
17	Reductions in stress urinary incontinence episodes: What is clinically important for Women? 2009 ·Neurourology and Urodynamics ·Ilker Yalcin, Guangbin Peng, Lars Viktrup, Richard C. Bump	38
18	Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer 2009 ·Journal of Clinical Oncology ·Craig H. Reynolds, Coleman K. Obasaju, Michael J. Schell, Xueli Li, Zhong Zheng, David Boulware, J. R. Caton, Linda C. DeMarco, Mark Allen O’Rourke, Gail S. Wright, Kristi A. Boehm, Lina Asmar, Jane Bromund, Guangbin Peng, Matthew Monberg, Gerold Bepler	138
19	Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS) 2008 ·Supportive Care in Cancer ·Richard J. Gralla, Martin J. Edelman, Frank C. Detterbeck, Thierry Jahan, David Loesch, Steven Limentani, Ramaswamy Govindan, Guangbin Peng, Matthew Monberg, Coleman K. Obasaju, Mark A. Socinski	14
20	P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Craig H. Reynolds, Paul Conkling, Donald Richards, James F. Fitzgibbons, James C. Arseneau, Kristi A. Boehm, Lina Asmar, Jane Bromund, Guangbin Peng, Coleman K. Obasaju	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact